Efficacy, safety, and immunogenicity of recombinant insulin aspart (BioGenomics Limited) and NovoRapid® (Novo Nordisk) in adults with type 2 diabetes mellitus: a randomized, open-label, multicenter, phase-3 study

MLA

Sneha A. Dongre, et al. “Efficacy, Safety, and Immunogenicity of Recombinant Insulin Aspart (BioGenomics Limited) and NovoRapid® (Novo Nordisk) in Adults with Type 2 Diabetes Mellitus: A Randomized, Open-Label, Multicenter, Phase-3 Study.” Research in Pharmaceutical Sciences, vol. 19, no. 5, Oct. 2024, pp. 489–99. EBSCOhost, https://doi.org/10.4103/RPS.RPS_188_23.

APA

Sneha A. Dongre, Gauri A. Kulkarni, Akshay Mishra, Rutuja B. Deshmane, Nameeta Sonar, Kanica Yashi, Damodar Thapa, Nikhil Ghade, Sachin M. Kadoo, Archana R. Krishnan, & Sanjay M. Sonar. (2024). Efficacy, safety, and immunogenicity of recombinant insulin aspart (BioGenomics Limited) and NovoRapid® (Novo Nordisk) in adults with type 2 diabetes mellitus: a randomized, open-label, multicenter, phase-3 study. Research in Pharmaceutical Sciences, 19(5), 489–499. https://doi.org/10.4103/RPS.RPS_188_23

Chicago

Sneha A. Dongre, Gauri A. Kulkarni, Akshay Mishra, Rutuja B. Deshmane, Nameeta Sonar, Kanica Yashi, Damodar Thapa, et al. 2024. “Efficacy, Safety, and Immunogenicity of Recombinant Insulin Aspart (BioGenomics Limited) and NovoRapid® (Novo Nordisk) in Adults with Type 2 Diabetes Mellitus: A Randomized, Open-Label, Multicenter, Phase-3 Study.” Research in Pharmaceutical Sciences 19 (5): 489–99. doi:10.4103/RPS.RPS_188_23.